CTLA4 and neoplasm: Thus, two immunodominant neoantigens have been identified in methylcholanthrene (MCA)-induced sarcoma model, and mutant tumor antigen-specific T cells showed to be reactivated upon immunotherapy with PD-1 and/or CTLA-4 blockade, enabling an effective tumor rejection that could be boosted with neoepitope-based vaccination [70].